ArticleTranslational lung cancer research2026
Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study.
Qian Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.